Immunity vs Nature Immunology

For immunologists with a high-impact finding, the choice usually comes down to two journals: Immunity (Cell Press, IF 26.3) and Nature Immunology (Nature Portfolio, IF 27.6). They cover identical scope - all aspects of immunology - at comparable prestige levels. From the outside, they look interchangeable.

They're not. The differences are in editorial model, review philosophy, format options, and the ecosystems they connect to. Immunity uses in-house Cell Press editors with the Cell Press transfer system and Multi-Journal Submission. Nature Immunology uses in-house Nature editors with the Nature Portfolio transfer cascade. The editorial cultures, shaped by these parent organizations, create meaningfully different experiences for authors.

This guide is for immunologists choosing between the two. Not which is "better" - they're both excellent - but which is better for your specific paper and your strategic goals.

Head-to-Head Comparison

Editorial Philosophy: Mechanism vs Significance

Both journals want mechanistic immunology. But where they draw the line between "enough mechanism" and "not enough" differs subtly.

Immunity (Cell Press) leans toward deeper mechanistic dissection. As a Cell Press journal, it inherits the family's emphasis on completeness - explaining HOW the immune system works at molecular resolution. Cell Press's editorial culture says: trace the pathway, show causation, validate across systems. Immunity editors explicitly note they require "deeper mechanism than Nature Immunology, which sometimes accepts more observational studies."

Nature Immunology leans toward significance and breadth. While mechanism is still essential, Nature Immunology places relatively more weight on the significance of the finding for the broader immunology community. A striking new observation with strong evidence (even if the molecular pathway isn't fully mapped) may get further at Nature Immunology than at Immunity.

This is a tendency, not a rule. Both journals publish mechanistically deep papers and both publish significant observations. But if your paper's strength is mechanistic completeness (the full pathway mapped from receptor to transcription factor), Immunity's editorial DNA is more aligned. If your paper's strength is a surprising finding with broad significance (even if the mechanism still has gaps), Nature Immunology may be more receptive.

The Ecosystem Advantage: Cell Press vs Nature Portfolio

The choice between Immunity and Nature Immunology is also a choice between ecosystems.

Immunity connects to Cell Press: Cell, Cancer Cell, Cell Metabolism, Neuron, Molecular Cell, Cell Reports, and iScience. If rejected from Immunity, you can transfer to Cell Reports (solid biology journal, IF 6.7) or iScience (guaranteed review). The Multi-Journal Submission system lets you submit to multiple Cell Press journals simultaneously, avoiding serial rejections.

Nature Immunology connects to Nature Portfolio: Nature, Nature Medicine, Nature Communications, Communications Biology, and Scientific Reports. If rejected, you can transfer to Nature Communications (IF 15.7, ~20% acceptance) or Communications Biology. The cascade is well-oiled and editors actively enable transfers.

The key strategic difference: Nature Communications (IF 15.7) is a substantially higher-impact landing spot than Cell Reports (IF 6.7). If your paper is rejected from both specialist journals, the Nature Portfolio offers a more prestigious fallback. On the other hand, Cell Press offers Multi-Journal Submission, which can save weeks by avoiding serial rejections entirely.

Choose Immunity if: you want access to the Cell Press family, especially if your work might also fit Cancer Cell or Cell Metabolism. Choose Nature Immunology if: you want the Nature Communications safety net or if your work might be relevant to Nature Medicine.

Format and Review Experience

The format options differ meaningfully.

Immunity offers Article (≤7,000 words, 7 figures) and Report (≤4,000 words, 4 figures). The Report format is genuinely useful for focused findings that don't need the full Article treatment. Cell Press also requires STAR Methods with Key Resources Tables, graphical abstracts (for Articles), and highlights. The formatting overhead is higher than Nature journals.

Nature Immunology offers Article (3,000–4,000 words, 8 display items) and Letter (~2,500 words, 5 items). The Letter format is an underused pathway - it's shorter than Immunity's Report and can be ideal for high-impact findings that are complete but focused. Nature journals generally have lighter formatting requirements at initial submission.

Review experience: Both journals use single-blind peer review by 2–3 expert reviewers. Nature Immunology offers double-blind review as an opt-in (available since 2015), which Immunity does not. Both employ reviewer cross-consultation to resolve conflicts.

Immunity offers Sneak Peek, where papers can appear on SSRN as preprints during review. Nature Immunology accepts papers previously posted on bioRxiv but doesn't have an integrated preprint system.

Timing: Immunity's desk-to-publication pipeline for accepted papers runs ~10 weeks. Nature Immunology's median submission-to-acceptance is ~300 days. Immunity is generally faster end-to-end.

Impact and Prestige

Nature Immunology currently leads in raw Impact Factor (27.6 vs 26.3). But Immunity leads in CiteScore (46 vs 32.7) and H-index (475 vs 424), reflecting a longer track record and more accumulated citations. In practice, the prestige difference is negligible - both are recognized as the top specialist immunology journals, and hiring committees, grant reviewers, and department chairs treat them as equivalent.

The choice shouldn't be driven by a 1.3-point IF gap. It should be driven by which editorial philosophy matches your paper, which ecosystem serves your strategic needs, and which format suits your story.

One practical note: if your immunology paper has strong clinical or translational implications, consider whether Nature Medicine (IF 50.0) or Science Immunology (IF ~24) might actually be better targets. Both Immunity and Nature Immunology are for fundamental immunology. If the clinical angle is your paper's strongest feature, a translational or clinical journal may serve it better.